KRAS / RAS 靶向 — 从平台化到 Ph3 验证
现场把这件事从「G12C 单药还能撑多久」改写成「谁先把 1L 胰腺癌做成标准治疗」。daraxonrasib 的 III 期是目前唯一的 RAS 抑制剂总生存阳性；G12D 的 zoldonrasib 与 VS-7375 还在 I 期，数字好看但样本小，不能直接互比。
@AACR
Top Trials from Day 3
RMC-9805-001 | SHR-1316-III-303 | RMC-6236-001 | CheckMate 77T | D3S-001-100 | INFINITY | DiscovHER PAN-206 | RASolute 303 | MYTHIC | CTEP 10355
#AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX
Heat 0 · 0 likes · 0 replies · 0 reposts
Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam
Read the abstract →Ferdinandos Skoulidis, Kathryn C. Arbour, Sanjay Popat, Colin R. Lindsay, Hidehito Hironouchi, Gérard Zalcman, Alessandra Curioni-Fontecedro, Jarushka Naidoo, Adrianus J. de Langen, Lin Tao, Erica Su, Minoti Hiremath, Achim Rittmeyer, Melissa Johnson
Read the abstract →Kayla Tyskiewicz, Markus Hippich, Tristan Cates, Gervaise Henry, Gilad Silberberg, Nicole Spanburg, Madeline Westcott, Daniel Ciznadija, Michael Boice, Paul Heverly, Frank Smith, Marianna Zipeto, Stefano Cairo, Sebastian Brabetz
Read the abstract →Ishita Saha, Santanu Bhattacharya, Debabrata Mukhopadhyay, Hani M. Babiker
Read the abstract →Seema nadir, Sumaiya Binte Hamid, Mati Ur Rehman, Azhar Hussain Rajabali, Kulsoom K. Ghias, Arooj Shafiq
Read the abstract →Source: Bhaarath PG · x.com